The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.

Drug Des Devel Ther · 2021 · PMC8203199 · PMID 34140766

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

In this study, the dose of 200 mg failed to reach significance.

also in 4,113 other papers

borderline significantno p-value reported

There was borderline significant improvement in ADL for the 100 mg/day, as well as UPDRS III (responders) for the 50 mg/day group.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.